Skip to main content
Quest Diagnostics

Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans

Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans

Authors: Li Y, Heer AK, Sloane HS, Edelstein DL, Tie J, Gibbs P, Barzi A

Citation: JAMA Health Forum. 2024 May 3;5(5):e241270. doi: 10.1001/jamahealthforum.2024.1270.

Specialties: Oncology, Genetics

Download key summary

Related content

Publication
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study
Conference Presentation
The Effect of a Digital Health Coaching (DHC) Program on Patient Reported Outcomes of Women with Breast Cancer
Publication
Revolutionizing Digital Pathology With the Power of Generative Artificial Intelligence and Foundation Models
Test FAQ
Haystack MRD Testing
Audio Podcast
Optimize Oncology Care with Clinical Pathways
On-Demand Webinar
Hereditary Cancer Care Starts in Primary Care

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.